Dianthus Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins to treat severe autoimmune diseases including myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company's lead candidate, claseprubart, is a selective C1s complement inhibitor designed to block antibody-driven immune responses while preserving other immune pathways, administered via pre-filled pen for patient convenience. Dianthus generates revenue through licensing agreements with regional partners—Tenacia Biotechnology in Greater China and Leads Biolabs outside Greater China—and plans to commercialize its therapies through internal infrastructure and external partnerships following regulatory approval, relying on contract manufacturers for production and maintaining a patent portfolio covering its complement-targeting approach.